Inflammatory Bowel Disease
VIDEO: Stelara, Entyvio in elderly patients with Crohn’s disease
In an exclusive video with Healio Gastroenterology, Benjamin Click, MD, Cleveland Clinic, spoke about the safety and efficacy of Stelara and Entyvio in elderly patients with Crohn’s disease.
Chronic fatigue links to increased cost among patients with IBD
Fatigue associated with increased healthcare use and cost among patients with inflammatory bowel disease, according to a presentation at Digestive Disease Week.
Higher antimicrobial gene burden in patients with cirrhosis vs. IBD, other diseases
Patients with cirrhosis had a higher abundance of beta-lactamase, vancomycin and quinolone genes in their gut microbiota compared with patients with inflammatory bowel disease, chronic kidney disease and diabetes, according to a presentation from Digestive Diseases Week.
VIDEO: Low-dose aspirin for VTE prophylaxis after IBD surgery
Stefan Holubar, MD, MS, Cleveland Clinic, told Healio low-dose aspirin VTE extended prophylaxis following inflammatory bowel disease surgery was safe and cost-effective compared with enoxaparin or no prophylaxis.
April top 10 in GI: colorectal cancer, AGA guidance, IBD
TDM does not improve treatment efficacy during Remicade therapy for inflammatory diseases
Proactive therapeutic drug monitoring vs. standard therapy did not significantly improve clinical remission rates over 30 weeks in patients with immune-mediated inflammatory diseases initiating Remicade therapy, according to study results.
Q&A: Remicade treatment weakens COVID-19 antibody response in IBD
Patients who received Remicade for inflammatory bowel disease had weakened anti-COVID-19 antibody responses following a single vaccination dose, according to research published in Gut.
Serum LRG useful biomarker of endoscopic activity in IBD patients on Humira
Serum Leucine-rich alpha-2 glycoprotein was a useful biomarker of endoscopic activity in patients with Crohn’s disease and ulcerative colitis taking Humira, according to a study published in Journal of Gastroenterology.
IBD therapies do not increase adverse events in pregnancy
Exposure to biologics, thiopurines or combination therapy for inflammatory bowel disease during pregnancy did not increase maternal or infant adverse events at birth or in 1-year of life, according to a study published in Gastroenterology.
COVID-19 in GI: 1 year later
In March 2020, there was so much we did not know about COVID-19 and how it would impact the world of gastroenterology. Were our patients at risk? How long would endoscopy be disrupted? When will things be normal again?